Aeterna Zentaris Inc. is a specialty biopharmaceutical company developing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin) for diagnosing growth hormone deficiency. AEZS-150 and AEZS-130 are in preclinical trials for treating chronic hypoparathyroidism and amyotrophic lateral sclerosis, respectively. The company has licensing agreements with University of Wuerzburg, Consilient Health, NK MEDITECH, Er-Kim Pharmaceuticals Bulgaria Eood, and University of Sheffield. Aeterna Zentaris was incorporated in 1990 and is headquartered in Toronto, Canada.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 1.7 |